Display Settings:

Format

Send to:

Choose Destination
JAMA. 2011 Sep 28;306(12):1344-51. doi: 10.1001/jama.2011.1364.

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

Author information

  • 1Department of Medicine, Massachusetts General Hospital, 50 Staniford St, Ninth Floor, Boston, MA 02114, USA. mbarry@partners.org

Abstract

CONTEXT:

Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg/d).

OBJECTIVE:

To determine the effect of saw palmetto extract (Serenoa repens, from saw palmetto berries) at up to 3 times the standard dose on lower urinary tract symptoms attributed to BPH.

DESIGN, SETTING, AND PARTICIPANTS:

A double-blind, multicenter, placebo-controlled randomized trial at 11 North American clinical sites conducted between June 5, 2008, and October 10, 2010, of 369 men aged 45 years or older, with a peak urinary flow rate of at least 4 mL/s, an American Urological Association Symptom Index (AUASI) score of between 8 and 24 at 2 screening visits, and no exclusions.

INTERVENTIONS:

One, 2, and then 3 doses (320 mg/d) of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks.

MAIN OUTCOME MEASURES:

Difference in AUASI score between baseline and 72 weeks. Secondary outcomes included measures of urinary bother, nocturia, peak uroflow, postvoid residual volume, prostate-specific antigen level, participants' global assessments, and indices of sexual function, continence, sleep quality, and prostatitis symptoms.

RESULTS:

Between baseline and 72 weeks, mean AUASI scores decreased from 14.42 to 12.22 points (-2.20 points; 95% CI, -3.04 to -0.36) with saw palmetto extract and from 14.69 to 11.70 points (-2.99 points; 95% CI, -3.81 to -2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo (upper bound of the 1-sided 95% CI most favorable to saw palmetto extract was 1.77 points, 1-sided P = .91). Saw palmetto extract was no more effective than placebo for any secondary outcome. No clearly attributable adverse effects were identified.

CONCLUSION:

Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00603304.

Comment in

PMID:
21954478
[PubMed - indexed for MEDLINE]
PMCID:
PMC3326341
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 3

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk